Skip to main content
. 2021 Dec 18;9(12):1499. doi: 10.3390/vaccines9121499

Table 1.

Populations studied.

Population Vaccine SARS-CoV-2 Infection
COVID-19
(n = 18)		 Non-vaccinated Recovered from previous COVID-19 (RT-qPCR+ <70 days), no longer reporting symptoms
Healthy controls
T0 (n = 33)		 Non-vaccinated, enrolled immediately before the 1st mRNA BNT126b2b vaccine injection Subjects with no previous SARS-CoV-2 infection
Vaccinated
T1 (n = 28)		 Vaccinated: subjects of the healthy control group, retested 15 days after the 2nd mRNA BNT126b2b vaccine injection Subjects with no previous SARS-CoV-2 infection